Abstract C48: Neoadjuvant endocrine therapy in locally advanced hormone receptor positive (HR+) breast cancer (BC) in a low-resource, middle-income setting (Guatemala)

Conclusions: Neoadjuvant tamoxifen is a tolerable, acceptable, and less expensive option for pts with HR+ locally advanced BC in a middle-income, low-resource setting, with good rates of adherence and clinical response. This has implications for other LMIC, but further studies are needed to better define patient selection, applicability, and length of treatment of neoadjuvant tamoxifenCitation Format: Laila S. Agrawal, Mei-Ling Pereira, Ingrid A. Mayer, Eduardo Gharzouzi. Neoadjuvant endocrine therapy in locally advanced hormone receptor positive (HR+) breast cancer (BC) in a low-resource, middle-income setting (Guatemala). [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr C48.
Source: Cancer Epidemiology Biomarkers and Prevention - Category: Cancer & Oncology Authors: Tags: Breast Cancer: Poster Presentations - Proffered Abstracts Source Type: research